Ascletis ASC40 Phase III Success in Acne Vulgaris
Ascletis Pharma Inc (HKG: 1672) announced positive top‑line results from the open‑label Phase III study (NCT06248008)...
Thermo Fisher Reports Q4 Revenue Growth on AI Innovation
Thermo Fisher Scientific Inc. (NYSE: TMO) reported fourth‑quarter revenue of $12.21 billion , up 7% year‑on‑year (YOY),...
TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases
TYK Medicines, Inc. (HKG: 2410) announced that its Category 1 drug asandeutertinib (TY‑9591), a third‑generation EGFR...
Takeda Q3 Revenue Drops 3.3% on VYVANSE Generics, Raises Full-Year Forecast
Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK) reported third‑quarter fiscal 2025 revenue of 3,411.2 billion yen (USD 22.17 billion), down...
Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong...
Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that a supplementary Biologics License Application (sBLA)...
Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
Suzhou Genhouse Bio Co., Ltd. submitted its initial public offering (IPO) filing to the Hong...
Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China
Sanofi (NASDAQ: SNY) reported full‑year 2025 revenues of EUR 43.626 billion (USD 47.8 billion), representing 9.9% growth at constant exchange...
Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China
Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...
United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial
United Laboratories International Holdings Ltd (HKG: 3933) announced that the U.S. Food and Drug Administration (FDA)...
Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a licensing agreement with ApolloBio Corp.,...
Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform
Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced a plan to increase capital investment...
Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered
Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for...
WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases
WuXi Biologics (HKG: 2269) announced a collaboration agreement with Guizhou Sinorda Biomedicineic Co., Ltd. to provide...
NeuShen Therapeutics Raises Series A+ for CNS Drug Development
NeuShen Therapeutics, a Sino‑US biotech focused on central nervous system (CNS) disorders, announced the completion...
Organon Completes $465M JADA System Sale to Laborie Medical
Organon (NYSE: OGN) announced the completed acquisition of its JADA system by Laborie Medical Technologies Corp....
MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study
MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino‑US biopharmaceutical company, announced it has received approval from...
Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that the National Medical Products Administration (NMPA)...
Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%
Servier announced a 16.2% year‑on‑year (YOY) revenue increase to EUR 6.9 billion (USD 7.52 billion) for the 2024/25 financial...